三鑫医疗(300453) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥331,158,893.25, representing a 21.34% increase compared to ¥272,919,002.98 in the same period last year[5] - Net profit attributable to shareholders for Q1 2024 was ¥53,618,659.09, up 19.72% from ¥44,785,584.88 in the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥46,793,480.66, reflecting a 28.61% increase from ¥36,384,675.79 year-on-year[5] - Basic and diluted earnings per share for Q1 2024 were both ¥0.1032, an increase of 19.03% from ¥0.0867 in the previous year[5] - Net profit for the quarter was ¥57,670,378.97, representing a 20.9% increase from ¥47,667,602.73 in the prior year[41] - Earnings per share (EPS) for the quarter was ¥0.1032, compared to ¥0.0867 in the previous year[43] Cash Flow - The net cash flow from operating activities reached ¥35,414,525.27, a significant improvement of 201.50% compared to a negative cash flow of -¥34,889,965.06 in the same quarter last year[5] - Operating cash inflow for the period reached ¥369,431,494.32, up from ¥293,209,742.43 in the previous period, representing a growth of approximately 26%[47] - Cash inflow from investment activities totaled ¥84,179,160.51, compared to ¥25,221,763.58 in the prior period, indicating a substantial increase[47] - Net cash flow from investment activities was -¥3,326,332.53, an improvement from -¥65,408,587.34 in the previous period[47] - Cash inflow from financing activities amounted to ¥50,250,000.00, down from ¥68,400,000.00 in the previous period[49] - Net cash flow from financing activities was -¥55,738,155.91, compared to a positive net flow of ¥60,845,893.26 in the prior period[49] - The ending balance of cash and cash equivalents was ¥174,641,673.04, down from ¥246,013,644.10 in the previous period[49] - The company received cash from the recovery of investments amounting to ¥82,241,110.00, significantly higher than ¥23,948,282.00 in the previous period[47] - Total cash outflow for operating activities was ¥334,016,969.05, slightly up from ¥328,099,707.49 in the previous period[47] - The company reported a cash inflow of ¥46,599,084.12 from other operating activities, compared to ¥26,006,178.31 in the previous period, marking an increase of approximately 79%[47] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,018,346,930.01, a slight decrease of 0.61% from ¥2,030,807,833.80 at the end of the previous year[5] - The company reported a total current assets of ¥659,638,138.87 as of March 31, 2024, down from ¥691,760,101.72 at the beginning of the period, representing a decrease of approximately 4.6%[24] - Cash and cash equivalents decreased to ¥182,836,879.66 from ¥221,286,623.55, a decline of about 17.3%[24] - Accounts receivable increased to ¥94,668,888.24 from ¥86,638,303.72, reflecting an increase of approximately 9.5%[24] - Inventory decreased to ¥190,922,514.97 from ¥199,382,114.37, a reduction of about 4.7%[27] - Total liabilities decreased to ¥683,458,742.99 from ¥696,843,705.65 year-over-year[33] - Non-current liabilities increased to ¥182,471,827.30 from ¥131,890,540.13 in the previous year[33] Shareholder Information - The company reported a total of 18,277 common shareholders at the end of the reporting period[15] - The company holds a total of 156,451,403 shares under lock-up agreements, which is 75% of the shares held by key executives[23] - The company has a total of 8,295,650 shares in its repurchase account, accounting for 1.60% of the total shares held by the top 10 shareholders[22] Research and Development - Research and development expenses for Q1 2024 were ¥12,130,470.58, a 62.09% increase from ¥7,483,945.25 in the same period last year, indicating increased investment in R&D[10] - Research and development expenses increased to ¥12,130,470.58, up 62.5% from ¥7,483,945.25 year-over-year[37] Operating Costs - Operating costs amounted to ¥272,638,774.30, up 20.5% from ¥226,181,202.20 in the same period last year[37] - The company reported a gross profit margin of approximately 17.6% for the quarter, compared to 16.9% in the previous year[37]